5 Covid Related Stocks To Consider This Month

Biogen Inc. (NASDAQ: BNTX) is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company’s pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.

Oncotelic Therapeutics, Inc. (OTC: OTLC) is an artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-β RNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients. OT-101 also has shown activity against SARS-CoV-2 and has completed a phase 2 trial against COVID-19 with data cleaning and datalock ongoing.

Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company also acquired PointR Data Inc. (“PointR”) in November 2019.

The company recently announced that it has submitted clinical study protocol to the US FDA for the initiation of a Phase 2 Trial (designated “M201”) for OT-101, the Company’s TGF-β inhibitor, in combination with Anti-PD-1 (Pembrolizumab/Keytruda®) as a treatment for patients with Malignant Pleural Mesothelioma (MPM).

M201: Phase 2 Trial of TGF-β Inhibition (OT-101) with Anti-PD-1 (Pembrolizumab) in Patients with Malignant Pleural Mesothelioma (MPM) Failing to Achieve or Maintain Response to Checkpoint Inhibition.

OT-101 is a first-in-class anti-TGF-β ribonucleic acid (“RNA”) therapeutic that has exhibited single agent activity in relapsed/refractory cancer patients in multiple clinical trials. OT-101 has also demonstrated activity against the SARS-CoV-2 virus, the virus that causes COVID-19, and is currently being evaluated in the Company’s C001 clinical trial against hospitalized severe COVID-19 patients. Both tumor cells and SARS-Cov-2 induce TGF-β as part of their immune evasion mechanism. Consequently, inhibiting TGF-β by OT-101 is expected to impact both cancer and COVID.

The OT-101 oncology program (“OT-101-ONC”) is designed to assess the impact of OT-101 across multiple cancer indications where local tumoral secretion of TGF-β suppressed the clinical activity of checkpoint inhibitors, CAR-T, and vaccine. The OT-101-ONC program has been moving forward steadily through strategic alliance with top pharmaceutical companies. Of note is the biomarker program spanning mesothelioma, glioblastoma, lung and colorectal cancers, where AI driven transcriptome analyses will be used to derive the predictive biomarker for TGF-β therapeutics such as OT-101.

Fulgent Genetics, Inc. (NASDAQ: FLGT), together with its subsidiaries, provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, adaptive learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves insurance, hospitals, and medical institutions. It sells its tests through internal sales force, as well as through independent sales representatives in the United States and internationally. Fulgent Genetics has collaboration with PWNHealth to provide at-home COVID-19 test capabilities; and has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

NRX Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage small molecule pharmaceutical company, develops various therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company’s pipeline includes medicinal candidates in Phase 2 and Phase 3 trials for COVID-19-related lung injury and acute respiratory distress. Its products include ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure; and NRX-100/101, an investigational pre-commercial drug for treating bipolar depression in patients with acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Contents published in this website contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FastMoneyLeaks undertakes no obligation to update such statements. FastMoneyLeaks was not compensated by companies mentioned in this article. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Advertisements received by you are not a solicitation or recommendation to buy securities of the advertised company.

 

Recent

A Host of Companies are Seeking to Make The Metaverse Happen: AXXA, NVDA, MTTR, U

Regardless of how markets perform next week or next month, there are some areas that should be very profitable over the long term. And...

These three penny stocks are very liquid and have been very popular among investors in the past

Penny stocks may be volatile, but with due diligence, some hidden treasures may be found.  These three penny stocks are very liquid and have been...

Golden Star Enterprises Ltd. (GSPT) saw new developments that hasn’t reflected in its shares price yet

Due to the pandemic, however, the importance of the technology sector increased enormously. In terms of industry specifics, IDC projects that the technology industry...

5 Covid Related Stocks To Consider This Month

Biogen Inc. (NASDAQ: BNTX) is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological,...

3 Entertainment Stocks To Consider Buying NOW: Cinedigm Corp., (CIDM), UMAX Group Corp. (UMAX), AMC Entertainment Holdings, Inc. (AMC)

The production and distribution of film and audiovisual works is one of the most dynamic growth sectors in the world. The world's entertainment and media...

3 Penny Stocks To Consider Before New Year: Asia Broadband Inc. (AABB), Two Hands Corporation (TWOH), US Energy Initiatives Corp (USEI)

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian...

The Race for the Multi Billion Dollar Sport Nutrition Market is On

The Global Sports Nutrition Market was valued at $24.25B in the base year 2020, and is projected to reach $47.92B by 2027, with a...

These 4 Bitcoin Mining Stocks Offer an Alternative Way to Play Crypto

Bitcoin mining is the process of creating new bitcoin by solving puzzles. It consists of computing systems equipped with specialized chips competing to solve...

Astro Aerospace Ltd. (ASDN) Shares on Watch as The Market for Flying Cars is expected to Reach $1.5 Trillion by 2040

The market for flying cars, now known as electric air taxis, should continue to mature during this decade, soaring to $1.5 trillion globally by...

Stocks to Watch as Investors Monitor Omicron Variant

Covid-19 cases are surging worldwide and a number of countries have imposed fresh restrictions in an effort to curb the spread of a new...

3 CBD Stocks to Buy Ahead of the 3rd-Green Wave Rebound

As more and more states legalize marjiuana, federal legalization in the U.S. seems inevitable. Not only are more states passing legislation to permit recreational...

3 Nutritional Growth Stocks to Watch: Herbalife Nutrition (HLF), Torque Lifestyle Brands Inc. (TQLB) and Else Nutrition Holdings inc. (OTC: BABYF)

According to a recent report from Grand View Research, the global sports nutrition market size was valued at $10.7 billion in 2020 and is...

Sprouts Farmers Market Inc, (SFM) Two Hands Corporation, (TWOH) and United Natural Foods, Inc. (UNFI), on Watch as Food remains one of the thriving...

Food remains one of the thriving industries worldwide, given its essential business nature and a strong connection to consumers. In 2020, global food industry...